+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sustained Release Injectables

  • ID: 3608075
  • Report
  • August 2021
  • Region: Global
  • 185 Pages
  • Greystone Associates
What are the Major Factors Driving Sustained Release Injectable Drug Demand?

FEATURED COMPANIES

  • Alkermes
  • Aurobundo
  • DURECT
  • Midatech
  • OctoPlus
  • Roche
Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing.

Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.

What You Will Learn

  • What are the marketed sustained release injectable drug products, what sustained release formulation technologies are used, and who markets them?
  • What are the major factors driving sustained release injectable drug demand?
  • What sustained release injectable drug candidates are in late-stage clinical development and what is their potential impact?
  • How important are drug developer-formulation technologist relationships in the sustained release market segment, and what are the key alliances in the industry?
  • What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for sustained release injectable drug products?
  • In what therapeutic market segments do sustained release injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate?
  • What are the significant economic, technology, and regulatory factors affecting the market for sustained release injectables?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Alkermes
  • Aurobundo
  • DURECT
  • Midatech
  • OctoPlus
  • Roche

1. Executive Summary


  • Injectable Drug Market Dynamics
  • The Trend toward Self-Administration
  • Injectable Drug Formulation Technology
  • Innovation in Injectable Device Designs
  • Therapeutic Demand Drivers

2. Market Factors


  • Competitive Landscape
  • Risk Factors

3. Sustained Release - Branded Formulation Technologies


  • Biodegradable Polymers
  • Branded SR Formulation Technologies
  • Physical Process Control Methods

4. Sustained Release Injectables - Development Factors


  • Formulation Factors
  • Stability
  • Lyophilization
  • Packaging
  • Administration Factors

5. SR Injectables - Product Analysis & Market Sector Forecasts


Addiction


  • Naltrexone
  • Diabetes
  • Exenatide

Infectious Disease


  • Interferon

Hormone Deficiency


  • Estradiol
  • Somatropin
  • Testosterone

Metabolic Diseases


  • Acromegaly
  • Lanreotide
  • Octreotide

Neurology


  • Aripiprazole
  • Fluphenazine
  • Haloperidol
  • Paliperidone
  • Olanzapine
  • Risperidone

Oncology


  • Leukemia
  • Vincristine
  • Lymphoma
  • Cytarabine
  • Prostate
  • Goserelin
  • Leuprolide
  • Triptorelin

Pain Management


  • Bupivacaine

Reproductive Health


  • Endometriosis

6. Company Profiles


Note: Product cover images may vary from those shown
  • Alkermes
  • Amylin
  • AntriaBio
  • Ascendis Pharma
  • AstraZeneca
  • Aurobundo
  • Avadel
  • Biomarin
  • Camurus
  • Critical Pharmaceuticals
  • DURECT
  • Eli Lilly Enzon
  • Ipsen
  • Janssen
  • NanOlogy
  • Novartis
  • OctoPlus
  • Oakwood Laboratories
  • PharmaSophia
  • Pacira
  • PhaseBio Pharmaceuticals
  • Recipharm AB
  • Roche
  • Sanofi
  • Taiwan Liposome Company
  • Xbrane Biopharma
  • Talon
  • Octoplus
  • Midatech
  • MedinCell
Note: Product cover images may vary from those shown